An interventional study of Exergame+Neurofeedback and Exergame [alone] in Parkinson Disease, sponsored by University of Leicester. Recruiting at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2026-04-28.
Sponsored by University of Leicester · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 246 studies in Parkinson Disease with a site in United Kingdom — 55 open to participants now, 66 under way, 5 of them phase 3. Parkinson Disease · United Kingdom.
Among the 246 studies in Parkinson Disease with a site in United Kingdom, this one is the 83rd largest by planned enrollment of the 183 interventional ones that give a count, is one of 20 that started in 2023, is one of 58 with no phase, reaches primary completion later than 30 of the 65 other live ones, and was the 193rd registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →55 of the 246 studies in Parkinson Disease with a site in United Kingdom are open now. Recruiting first, the newest first:
Northumbria University · Sites in United Kingdom
Ages 50+
Hoffmann-La Roche · Sites in United Kingdom, United States, China and 2 more countries
Ages 40–85
Heriot-Watt University · Sites in United Kingdom
Ages 18+
Queen's University, Belfast · Sites in United Kingdom
Ages 18+
University Hospital Tuebingen · Sites in United Kingdom, France, Germany and 4 more countries
Ages 35–80
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
246 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 48 · Phase 3 46 · Phase 4 6
First in 1999; this study’s year is marked. 20 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 80 across the 183 interventional studies, 100 across the 62 observational. Of the 152 that completed or were terminated, 45 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 246 have an industry lead sponsor. The 10 most frequent:
University of Leicester is the lead sponsor of 172 studies on the registry; 53 are open to participants now.
University of Leicester has 1 study filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
15 of the studies in Parkinson Disease with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05986643University of LeicesterBrain Training to Improve Balance in Parkinson's Disease | 2026-12 |
| NCT05635409Region SkaneA Trial to Determine the Safety and Tolerability of Transplanted Stem Cell Derived Dopamine Neurons to the Brains of Individuals With Parkinson's Disease | 2027-01 |
| NCT02760108University College, LondonParkinson's Families Project | 2027-01 |
| NCT07882108Cambridge University Hospitals NHS Foundation TrustGinger-PD: Ginger as a Modifier of Ghrelin Levels and Gut Function in Parkinson's Disease | 2027-03-01 |
| NCT07189468University Hospital, ToulouseAI-based Progression and Medication Response Prediction Study in Parkinson's Disease | 2027-04-01 |
Add all 15 to your calendar (.ics) → With an account.
Among the 246 studies in Parkinson Disease with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
People living with Parkinson's (PwP) rank balance problems amongst the most disabling symptom. Over time, balance function continues to decline and PwP go on to fall, affecting between 45-68% of PwP. Falling directly impacts upon the individuals' quality of life (QoL), as it prevents patients from doing everyday activities, and places PwP at greater risk of other medical problems, such as fractures.
New treatments are urgently needed to improve balance and reduce falls in order to improve QoL for PwP. The aim of this project is to achieve these goals by using exercise to alter brain activity. Supporting our idea, are previous studies that show both exercise alone as well as changing brain activity at rest via visual feedback (similar to how breathing can be controlled to lower blood pressure), can be used to rehabilitate balance. Here researchers test the idea that better results can be achieved for PwP, if a specific exercise program is used as the feedback to change brain activity.
PwP will be assigned randomly into 2 groups, one receiving the exergaming physical therapy (PT) alone with a placebo feedback and, the second group will be required to change brain activity using exercise feedback to change brain activity.
Each intervention will be performed 3 times/week with each session lasting 1⁄2 an hour, for 12 consecutive weeks. Participants are expected to attend 5 sessions over each fortnight. Assessments of balance will be made before and after all three treatments. This will allow us to measure any improvements and compare the 2 different methods to see which one improves balance the most in PwP.
This is a multi-centre centre study with University of Leicester and DeMontfort University being research sites. NHS organisations will be PIC sites where participants will be identified from. No medical data or access to patient medical records will be made. A PIC mNCA will be in place with NHS organisations.
For the design of the study, the investigators will adopt a double-blinded randomised clinical trial. This means that patients will not know their group allocation and the research associate that will be analysing the data will also not know what treatment the patient received.
Participants will be allocated into either group 1 or 2. Participants in both groups will both perform the exergame rehabilitation. The exergame, delivered in virtual reality, involves travelling down a road (to give optic flow) whilst dodging balls that move towards the participant by either shifting their body either to the left or right. Patients are also be instructed to stand still and catch stars that appear, and these will be used to score points and are associated with reward, ensuring motivation.
This exergame has been specifically designed to combine aspects of movement and balance control, body position, aerobic fitness, strengthening of core muscles and elements of co-ordination and speed.
The difference between the two groups will be the neuro-feedback provided during the performance of the exercise game. That is, group 1 will receive real feedback of brain activity whilst group 2 will receive a placebo which is called SHAM feedback. This corresponds to a random recording that has no association/correlation with on-going brain (EEG) activity. All participants will be randomly assigned a unique key code via a random computer generator, this will be facilitated by the Data Monitoring and Ethics committee. The research technician, that will perform the analysis of the data, will not be privy to particular intervention of interest. After the random allocation, but before the intervention, all participants will receive a familiarisation procedure for their allocation. Once the participants have successfully undergone the eligibility screening (see section below for details), participants will be randomly allocated to one of two groups. The research team will then conduct the familiarisation sessions before proceeding to the pre-intervention assessment (limit of stability at baseline). This will be followed by the 12-week training program (that requires attendance at 30 1/2hr sessions over the course of three months. This will be followed by the 12 week (end of program) post-intervention assessment to measure the limit of stability, and a further single follow-up at 6 months to asses for long-term retention of any benefits. The 12-week post-intervention testing sessions will occur within 72 hours, but no less than 24 hours following the preceding training session. For the Pre-and Post- assessments: this will include the : (i) the Limits of Stability test, (ii) Sensory Organisation Test, (iii) Parkinson's Disease Questionnaire, (iv) Berg Balance Scale, (v) Section III of UPDRS, (vi) mBEST, (vii) 6 Metre WalkTest, (viii) 4 Square Step Test, and (ix) the Daily Activities Questionnaire. All of the aforementioned measures are openly available and do not require any licenses/permission to use. Accordingly, there will not be any need to share data with the license holders.
VISIT 1:
In the first visit the research team will firstly ensure that the PLwP meet the eligibility criteria and that none of the exclusion criteria apply. Only those eligible will be randomly allocated to one or two groups, and the research team will measure using posturography and walking assessments to obtain a baseline balance score. The research team will also complete questionnaires, including the Parkinson's Disease Questionnaire, Berg Balance Scale, Section III of the UPDRS, and Daily Activities Questionnaires. The research team will also take a brief medical history. This initial visit will take place at the balance testing laboratory at DeMonfort University.
12 WEEK TRAINING PROGRAMME: During the 12-week training programme, participants will be asked to attend the balance laboratory at the University of Leicester, where either the exergame activity with feedback from brain activity or no feedback will be performed. These training sessions will last half an hour in total, and it is expected patients to complete 5 sessions over the course of a 2- week period. An online booking system will be used to manage the sessions. Participants will be allowed to miss a total of 6 sessions in total across the whole of the 3-month intervention program. Missing any more that this would compromise the integrity of the data.
POST INTERVENTION:
A post-intervention will be arranged immediately at the end of the training programme, then again at 3 and 6 months respectively. During these post-interventions, measurements will be taken from using the posturography and walking assessments to obtain a baseline balance score. Questionnaires will be completed, including the Parkinson's Disease Questionnaire, Berg Balance Scale, Section III of the UPDRS, and Daily Activities Questionnaires. A brief medical history will be taken again. These visits will take place at the balance testing laboratory at DeMonfort University.
INTERVIEWFor the optional part of the study, an interview will be arranged to take the patients' and Carers views on the accessibility and tolerability of these interventions, these will take place roughly 2 weeks at the end of the final training session. An encrypted voice recorder will be used. Participant ID will be mentioned at the beginning of the recording so that participants remain anonymous. Recordings will be stored in a secure environment at the University before the recordings are transferred to university computers. Recordings will be immediately deleted as soon as the recordings have been transferred. The research team or an external transcribing company (a confidentiality agree will be in place), will transcribe the recordings for analysing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
People with Parkinson with mild-moderate disease and severe disability (but able to stand and walk unaided (Hoehn and Yahr stage ≤4) be eligible if:
As long as all criteria are met - we will not impose any lower (assuming they are adults) or upper age limit for recruitment.
Exclusion Criteria:
Six 5 minutes sets of participants standing on a balance board within virtual environment playing the exergame and receiving real neurofeedback with 1 minute rest between each set.
Behavioral: Exergame+Neurofeedback
Six 5 minutes sets of participants standing on a balance board within virtual environment playing the exergame and receiving SHAM neurofeedback with 1 minute rest between each set.
Behavioral: Exergame [alone]
Electroencephalography (EEG) is a device that measures the electrical activity of the brain (brain waves). There are several frequencies of brain waves when we are awake; alpha (medium), beta (fast), and theta (slow). Alpha frequencies of brain activity are linked to maintaining balance, with more alpha activity being associated with poorer balance. EEG neurofeedback treatment involves placing electrodes on a person's head to monitor and change brain activity by giving cued audio or visual feedback. It has been used in PwP to show improvements in balance and walking. Other preliminary research in PwP has shown that exercise can also improve balance.
The exergame, delivered in virtual reality, involves travelling down a road (to give optic flow) whilst dodging balls that move towards the participant by either shifting their body either to the left or right. They are also be instructed to stand still and catch stars that appear and these will be used to score points and are associated with a monetary reward, ensuring motivation. This group will receive SHAM feedback.
Also known as: Exergame
Balance Scores
Changes in balance scores using The Limits of stability (LOS) test. This dynamic balance score is measured using a commercially available system (Bertec CDP/IVRTM (Interacoustics)).The participants will be asked to stand barefoot on the centre of the force platform, and will be support by a secure harness throughout to prevent falls. The assessment requires each participant to move their centre of pressure (COP) towards an intended target in the following order: forward, forward right, right, backward right, backward, backward left, left and forward left. Movement velocity (degrees per second), maximal excursion (greatest distance \[cm\] achieved towards the intended target/maximal distance of target \[cm\]) and directional control (\[the amount of intended movement - amount of extraneous movement)/amount of intended movement\] × 100) will be measured, representing the maximum distance an individual can intentionally sway without losing balance or needing to take a step.
Time frame: 12 weeks
Sensory Organisation Scores
Changes in the Sensory Organisation test scores, calculated by an interval scale, with 100 indicating no sway and 0 indicating an uncompleted trial. This task comprises six different sensory conditions in quiet stance and measures the COP path in centimetres. The test progressively becomes harder by either distracting or removing visual and/or proprioceptive feedback. During sway-referenced conditions, erroneous sensory information is presented to the participant while the force platform measures the participant's ability to compensate by using other senses to maintain balance. The following sensory conditions will be used: * Condition 1: Eyes open and fixed support * Condition 2: Eyes closed and fixed support * Condition 3: Eyes open sway-referenced and support sway-referenced * Condition 4: Eyes open and support sway referenced * Condition 5: Eyes closed and support sway-referenced * Condition 6: Eyes open and sway-referenced with support sway-referenced
Time frame: 12 weeks
Daily Life Scores
Changes of activities in daily life. The investigators will use a validated questionnaire to asses functional improvements in activities associated with everyday living. Activities of Daily Living Questionnaire (ADLQ) - A questionnaire aimed for use with patients diagnosed with cognitive impairments, which assesses function in ADL tasks across 6 areas of life. A set of four descriptions of different competence levels; scores range from 0 to 3 where higher scores indicate greater impairment. A fifth response option, "don't know/has never done" is also available, and if this option is selected, the item is excluded from scoring.
Time frame: 12 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — We plan to share via open access platforms the study protocol and statistical analysis approach before commencing the trial.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Before the trial commences
Access criteria: No criteria
Started Aug 2023 (actual). Primary completion is estimated for Dec 2026, 40 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 40 months is above that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.